TKD:F:F-Takeda Pharmaceutical Company Limited (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 24.74

Change

+0.17 (+0.69)%

Market Cap

USD 38.84B

Volume

200.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRKC:F MERCK KGAA NAM.SP.ADR

-0.60 (-1.95%)

USD 68.55B
MRK:F Merck & Company Inc

-1.65 (-1.08%)

USD 67.36B
RDDA:F Dr. Reddy's Laboratories Limit..

-2.00 (-2.86%)

USD 59.15B
H6D0:F Haleon PLC

-0.08 (-1.84%)

USD 41.60B
TKDA:F Takeda Pharmaceutical Company ..

+0.20 (+1.61%)

USD 41.17B
H6D:F Haleon PLC

-0.10 (-1.12%)

USD 40.82B
TEV:F Teva Pharmaceutical Industries..

+0.20 (+1.18%)

USD 19.32B
3KY:F HANSOH PHARMAC. HD-00001

-0.26 (-11.11%)

USD 15.54B
SH0:F Shionogi & Co. Ltd

-1.30 (-9.35%)

USD 10.96B
NB3:F Neurocrine Biosciences Inc

+0.80 (+0.75%)

USD 10.71B

ETFs Containing TKD:F

CC4:PA Amundi Index Solutions - .. 2.75 % 0.00 %

-0.68 (-0.32%)

USD 0.42B
TCC4:F Amundi Index Solutions - .. 2.75 % 0.00 %

N/A

USD 0.55B
TCC4:XETRA Amundi Index Solutions - .. 2.75 % 0.00 %

-0.70 (-0.32%)

USD 0.55B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.89% 38% F 37% F
Dividend Return 365.19% 100% F 97% N/A
Total Return 361.31% 99% N/A 99% N/A
Trailing 12 Months  
Capital Gain -15.99% 44% F 32% F
Dividend Return 638.37% 97% N/A 97% N/A
Total Return 622.38% 99% N/A 98% N/A
Trailing 5 Years  
Capital Gain -20.55% 55% F 27% F
Dividend Return 1,766.20% 95% A 96% N/A
Total Return 1,745.65% 98% N/A 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.62% 55% F 36% F
Dividend Return 305.55% 100% F 99% N/A
Total Return 309.37% 97% N/A 95% A
Risk Return Profile  
Volatility (Standard Deviation) 220.22% 3% F 3% F
Risk Adjusted Return 138.75% 100% F 100% F
Market Capitalization 38.84B 99% N/A 95% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.